Compare Stocks → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BNOXNASDAQ:ERNANASDAQ:GTBPNASDAQ:TRVN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNOXBionomics$0.84-15.2%$0.98$0.83▼$6.41$6.85M-0.08106,953 shs3.72 million shsERNAEterna Therapeutics$1.90+3.8%$2.08$0.84▼$2.99$10.28M4.3110,064 shs17,360 shsGTBPGT Biopharma$3.75-2.8%$3.87$2.95▼$16.11$5.31M0.654.28 million shs17,663 shsTRVNTrevena$0.39-2.5%$0.41$0.30▼$1.35$7.15M1.1159,560 shs31,160 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNOXBionomics0.00%-16.83%-9.63%-29.41%-62.16%ERNAEterna Therapeutics0.00%-7.77%+6.74%+2.15%-9.09%GTBPGT Biopharma0.00%+1.90%+17.37%-14.77%-44.49%TRVNTrevena0.00%-2.50%-4.76%-31.69%-65.79%The only financial event in 2024 that matters (Ad)Man Who Predicted 2008 Crash Warns of Black Swan Financial Event in 2024 Porter Stansberry’s new documentary is going viral.Stream the documentary for free by clicking hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNOXBionomics2.6782 of 5 stars3.55.00.00.03.30.00.6ERNAEterna TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGTBPGT Biopharma2.5403 of 5 stars3.55.00.00.04.20.00.0TRVNTrevena1.6775 of 5 stars3.53.00.00.02.50.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNOXBionomics3.00Buy$9.00971.43% UpsideERNAEterna TherapeuticsN/AN/AN/AN/AGTBPGT Biopharma3.00Buy$150.003,900.00% UpsideTRVNTrevena3.00Buy$5.001,182.05% UpsideCurrent Analyst RatingsLatest TRVN, ERNA, BNOX, and GTBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2024TRVNTrevenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $5.004/2/2024TRVNTrevenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/21/2024BNOXBionomicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNOXBionomics$10K685.44N/AN/A$2.73 per share0.31ERNAEterna Therapeutics$70K146.84N/AN/A($0.63) per share-3.02GTBPGT BiopharmaN/AN/AN/AN/A$3.75 per shareN/ATRVNTrevena$3.12M2.29N/AN/A($0.80) per share-0.49Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNOXBionomics-$21.44MN/A0.00N/AN/AN/AN/AN/AN/AERNAEterna Therapeutics-$21.67M-$4.25N/A∞N/AN/A-1,466.71%-46.26%8/9/2024 (Estimated)GTBPGT Biopharma-$7.60MN/A0.00∞N/AN/A-135.49%-80.28%8/5/2024 (Estimated)TRVNTrevena-$40.29M-$2.68N/AN/AN/AN/A-1,018.15%-103.12%8/12/2024 (Estimated)Latest TRVN, ERNA, BNOX, and GTBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2024Q1 2024GTBPGT Biopharma-$2.70-$2.12+$0.58-$2.60N/AN/A5/15/2024Q1 2024TRVNTrevena-$0.37-$0.36+$0.01-$0.36N/A$0.02 million4/1/2024Q4 2023TRVNTrevenaN/A-$1.06-$1.06-$1.06$0.09 million($0.08) million3/14/2024Q4 2023ERNAEterna TherapeuticsN/A-$1.14-$1.14-$1.14N/A$0.02 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNOXBionomicsN/AN/AN/AN/AN/AERNAEterna TherapeuticsN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNOXBionomics0.013.81N/AERNAEterna Therapeutics3.030.790.79GTBPGT BiopharmaN/A2.152.15TRVNTrevena8.353.603.60OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNOXBionomics15.90%ERNAEterna Therapeutics70.55%GTBPGT Biopharma8.15%TRVNTrevena13.56%Insider OwnershipCompanyInsider OwnershipBNOXBionomics1.50%ERNAEterna Therapeutics35.43%GTBPGT Biopharma10.00%TRVNTrevena2.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBNOXBionomicsN/A8.16 million8.04 millionNot OptionableERNAEterna Therapeutics85.41 million3.49 millionNo DataGTBPGT Biopharma21.42 million1.28 millionOptionableTRVNTrevena2318.34 million17.90 millionOptionableTRVN, ERNA, BNOX, and GTBP HeadlinesRecent News About These CompaniesJune 2 at 6:54 AM | americanbankingnews.comTrevena (NASDAQ:TRVN) Coverage Initiated at StockNews.comMay 24, 2024 | americanbankingnews.comTrevena (NASDAQ:TRVN) Now Covered by StockNews.comMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Trevena Amid Strategic Focus on Promising Drug TRV045May 16, 2024 | msn.comTrevena Reports Progress in Pain and Epilepsy Treatment Development, Amid Financial AdjustmentsMay 15, 2024 | investorplace.comTRVN Stock Earnings: Trevena Beats EPS for Q1 2024May 15, 2024 | globenewswire.comTrevena Reports First Quarter 2024 Results and Provides Business UpdateApril 28, 2024 | finance.yahoo.comTrevena, Inc. (TRVN)April 28, 2024 | benzinga.comTrevena Stock (NASDAQ:TRVN), Analyst Ratings, Price Targets, PredictionsApril 21, 2024 | msn.comTrevena Cross free art exhibition featuring local artistsApril 18, 2024 | pharmaceutical-technology.comTrevena gets grant for pharmaceutical composition for modulating S1P1 receptor activityApril 18, 2024 | msn.comTrevena (TRVN) Price Target Decreased by 7.69% to 6.12April 5, 2024 | morningstar.comTrevena Inc TRVNApril 4, 2024 | msn.comDanny Huston, Graham Greene, Martin Sensmeier, Oliver Trevena & Devaughn Nixon Join Joel Kinnaman Thriller ‘Ice Fall', Filming Underway In BulgariaApril 3, 2024 | msn.comTrevena Ramps Up Efforts on TRV045, Turns Attention Away from OLINVYK Amid Challenging Hospital EnvironmentApril 2, 2024 | benzinga.comRecap: Trevena Q4 EarningsApril 1, 2024 | globenewswire.comTrevena Reports Fourth Quarter 2023 Results and Provides Corporate UpdateMarch 28, 2024 | pharmaceutical-technology.comTrevena gets grant for pharmaceutical process for preparing compound of formula (i)March 22, 2024 | pharmaceutical-technology.comTrevena files patent for treatment of acute respiratory distress syndrome using specific peptidesMarch 16, 2024 | msn.comTrevena Cross cafe reopening as the Palm Tree BistroMarch 14, 2024 | falmouthpacket.co.ukTrevena Cross Garden Centre, The Palm Tree BistroNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesPfizer Finds a Foothold After a Solid Q1 2024 Earnings ReportMay 6, 2024 6:10 AMView Pfizer Finds a Foothold After a Solid Q1 2024 Earnings ReportOkta, Inc. Stock Falls To Critical Level: What Happens Next?May 31, 2024 7:40 AMView Okta, Inc. Stock Falls To Critical Level: What Happens Next?Brinker International Heats Up on Spicy Earnings Beat and Raise May 6, 2024 6:20 AMView Brinker International Heats Up on Spicy Earnings Beat and Raise International Game Technology Isn’t Playing Games With Guidance May 21, 2024 6:25 AMView International Game Technology Isn’t Playing Games With Guidance Canopy Growth’s Earnings: Profitability Despite Industry ShiftsMay 31, 2024 7:30 AMView Canopy Growth’s Earnings: Profitability Despite Industry ShiftsAll HeadlinesCompany DescriptionsBionomicsNASDAQ:BNOXBionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.Eterna TherapeuticsNASDAQ:ERNAEterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.GT BiopharmaNASDAQ:GTBPGT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.TrevenaNASDAQ:TRVNTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.